Lexicon To Present At The 2014 Bank of America Merrill Lynch Healthcare Conference - KFDA - NewsChannel 10 / Amarillo News, Weather, Sports

Lexicon To Present At The 2014 Bank of America Merrill Lynch Healthcare Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Lexicon Pharmaceuticals, Inc.

THE WOODLANDS, Texas, May 9, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2014 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 13, 2014 at 1:00 PM PDT (4:00 PM EDT) in Las Vegas.  Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until June 13, 2014.

About Lexicon
Lexicon is a biopharmaceutical company focused on developing breakthrough treatments for human disease.  Lexicon currently has drug programs in clinical development for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

©2012 PR Newswire. All Rights Reserved.

  • Health WatchMore>>

  • House approves VA health care overhaul

    House approves VA health care overhaul

    Wednesday, July 30 2014 6:19 PM EDT2014-07-30 22:19:50 GMT
    With a new Veterans Affairs secretary in place and an August recess looming, Congress is moving quickly to approve a compromise bill to refurbish the VA and improve veterans' health care.
    The House overwhelmingly approved a landmark bill Wednesday to help veterans avoid long waits for health care that have plagued the Veterans Affairs Department for years.
  • Deportations halted at New Mexico processing center

    Deportations halted at New Mexico processing center

    Deportations halted at New Mexico processing center

    Artesia, NM - Officials at an immigration processing center in new mexico announced they will be halting all deportations for the time being.
    Artesia, NM - Officials at an immigration processing center in new mexico announced they will be halting all deportations for the time being.
  • $1,000 Sovaldi now hepatitis treatment of choice

    $1,000 Sovaldi now hepatitis treatment of choice

    Tuesday, July 29 2014 7:29 PM EDT2014-07-29 23:29:20 GMT
    A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
    The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.